PYRUKYND® (mitapivat) Tablets Commercial Prescription and myAgios Patient Support Services Enrollment

Download and fill out the PYRUKYND Enrollment Form to request prescription fulfillment for eligible patients and connect them to a dedicated myAgios Patient Support Manager (PSM). Be sure to include the patient’s HIPAA release authorization.

Download Enrollment Form

Fax the completed enrollment form to 1-800-951-7814.

Get started with enrollment

If assistance is needed in completing the PYRUKYND Enrollment Form, please see the myAgios Annotated Enrollment Form for step-by-step guidance on the prescription and enrollment process.

See annotated form

You may also call myAgios at 1-800-951-3889 with questions, Mon-Fri, 8 am to 6 pm ET.

Once the form is completed and faxed to myAgios, a dedicated myAgios Patient Support Manager will reach out to office staff and patients directly to provide support throughout the treatment process.

What is a Patient Support Manager?

Learn how PSMs can support patients

Want to know more about financial assistance available to patients?

See coverage support options

Learn about the phase 3 pivotal trial program

Learn more


Call myAgios Patient Support Services at 1-800-951-3889, Mon-Fri, 8 am to 6 pm ET


PYRUKYND is a pyruvate kinase activator indicated for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency.


Acute Hemolysis: Acute hemolysis with subsequent anemia has been observed following abrupt interruption or discontinuation of PYRUKYND in a dose-ranging study. Avoid abruptly discontinuing PYRUKYND. Gradually taper the dose of PYRUKYND to discontinue treatment if possible. When discontinuing treatment, monitor patients for signs of acute hemolysis and anemia including jaundice, scleral icterus, dark urine, dizziness, confusion, fatigue, or shortness of breath.

Adverse Reactions: Serious adverse reactions occurred in 10% of patients receiving PYRUKYND in the ACTIVATE trial, including atrial fibrillation, gastroenteritis, rib fracture, and musculoskeletal pain, each of which occurred in 1 patient. In the ACTIVATE trial, the most common adverse reactions including laboratory abnormalities (≥10%) in patients with PK deficiency were estrone decreased (males), increased urate, back pain, estradiol decreased (males), and arthralgia.

Drug Interactions:

  • Strong CYP3A Inhibitors and Inducers: Avoid concomitant use.
  • Moderate CYP3A Inhibitors: Do not titrate PYRUKYND beyond 20 mg twice daily.
  • Moderate CYP3A Inducers: Consider alternatives that are not moderate inducers. If there are no alternatives, adjust PYRUKYND dosage.
  • Sensitive CYP3A, CYP2B6, CYP2C Substrates Including Hormonal Contraceptives: Avoid concomitant use with substrates that have narrow therapeutic index.
  • UGT1A1 Substrates: Avoid concomitant use with substrates that have narrow therapeutic index.
  • P-gp Substrates: Avoid concomitant use with substrates that have narrow therapeutic index.

Hepatic Impairment: Avoid use of PYRUKYND in patients with moderate and severe hepatic impairment.

Please see full Prescribing Information for PYRUKYND.

This program is not intended as medical advice and patients should consult their healthcare team with questions related to their treatment.